GlassScriptPhysician profile
Crystal Rainville
NPI 1033187919
$1,618.32
in general payments reported to CMS, 2019-2025
23 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $274 · 2020: $206 · 2021: $443 · 2022: $123 · 2023: $168 · 2024: $220 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $573.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $572.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $315.09 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $243.67 | 2019-2021 | |
| Pfizer INC. | $109.70 | 2019-2024 | |
| Corium, LLC | $106.69 | 2022-2025 | Azstarys |
| Supernus Pharmaceuticals, INC. | $98.71 | 2021-2022 | |
| Ironshore Pharmaceuticals INC. | $91.15 | 2019-2020 | |
| Glaxosmithkline, LLC. | $83.33 | 2019-2024 | Bexsero, Rotarix |
| Seqirus USA INC | $79.23 | 2021-2024 | Flucelvax, Fluad Quadrivalent, Flucelvax Quadrivalent |
| Cranial Technologies, INC | $76.55 | 2024-2025 | Doc Band |
| Astrazeneca Pharmaceuticals LP | $61.83 | 2022-2024 | Flumist Quadrivalent |
| Alk-Abello, INC | $60.54 | 2023-2025 | Neffy, Odactra, Grastek |
| Sanofi-Aventis U.S. LLC | $45.88 | 2025 | |
| Collegium Pharmaceutical, INC. | $32.91 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $30.25 | 2021 | |
| Exeltis, USA INC. | $25.85 | 2024 | Slynd |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $22.85 | 2023 | |
| Merck Sharp & Dohme LLC | $22.49 | 2025 | Vaxelis, Enflonsia, Gardasil 9 |
| Sobi, INC | $21.74 | 2020 | |
| Verrica Pharmaceuticals INC. | $20.15 | 2024 | Ycanth |
| Phadia US INC. | $18.82 | 2019 | |
| Kaleo, INC. | $17.67 | 2019 | |
| Sanofi Pasteur INC. | $16.66 | 2022 | |
| Dermira, INC. | $16.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Rainville listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.